Hormone replacement therapy and risk of breast cancer: the role of progestins

References

• Breast cancer and hormone replacement therapy. Collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer. Lancet 1997; 350: 1047–59.
   Google Scholar
• Magnusson C, Baron JA, Correia N, Bergstrom R, Adami HO, Persson I. Breast-cancer risk following long-term oestr. Int J Cancer 1999; 81: 339–44.
   Google Scholar
• Persson I, Thurfjell E, Bergstrom R, Holmberg L. Hormone replacement therapy and the risk of breast cancer. Nested case-control study in a cohort of Swedish women attending mammography screening. Int J Cancer 1997; 72: 758–61.
   Google Scholar
• Persson I, Weiderpass E, Bergkvist L, Bergstrom R, Schairer C. Risks of breast and endometrial cancer after estrogen and estrogen-progestin replacement. Cancer Causes Control 1999; 10: 253–60.
   Google Scholar
• Ross RK, Paganini-Hill A, Wan PC, Pike MC. Effect of Hormone Replacement Therapy on Breast Cancer Risk: Estrogen Versus Estrogen Plus Progestin. J Natl Cancer Inst 2000; 92: 328–32.
   Google Scholar
• Schairer C, Lubin J, Troisi R, Sturgeon S, Brinton L, Hoover R. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA 2000; 283: 485–91.
   Google Scholar
• Colditz GA, Rosner B. Cumulative risk of breast cancer to age 70 years according to risk factor status: data from the Nurses’ Health Study. Am J Epidemiol 2000; 152: 950–64.
   Google Scholar
• Ewertz M. Influence of non-contraceptive exogenous and endogenous sex hormones on breast cancer risk in Denmark. Int J Cancer 1988; 42: 832–8.
   Google Scholar
• WHO I, AfRoC. Hormonal Contraception and postmenopausal hormonal therapy 72. Lyon, France: WHO, 1999.
   Google Scholar
• Jolleys JV, Olesen F. A comparative study of prescribing of hormone replacement therapy in USA and Europe. Maturitas 1996; 23: 47–53.
   Google Scholar
• Schneider HP. Cross-national study of women’s use of hormone replacement therapy (HRT) in Europe. Int J Fertil Womens Med 1997; 42: 365–75.
   Google Scholar
• Olesen C, Steffensen FH, Sorensen HT, Nielsen GL, Olsen J, Bergman U. Low use of long-term hormone replacement therapy in Denmark. Br J Clin Pharmacol 1999; 47: 323–8.
   Google Scholar
• Brett KM, Madans JH. Use of postmenopausal hormone replacement therapy: estimates from a nationally representative cohort study. Am J Epidemiol 1997; 145: 536–45.
   Google Scholar
• Topo P, Koster A, Holte A, Collins A, Landgren BM et al. Trends in the use of climacteric and postclimacteric hormones in Nordic countries. Maturitas 1995; 22: 89–95.
   Google Scholar
• Lawrence M, Jones L, Lancaster T, Daly E, Banks E. Hormone replacement therapy: patterns of use studied through British general practice computerized records. Fam Pract 1999; 16: 335–42.
   Google Scholar
• Townsend J. Hormone replacement therapy. assessment of present use, costs, and trends. Br J General Pract 1998; 48: 955–8.
   Google Scholar
• Connelly MT, Richardson M, Platt R. Prevalence and duration of postmenopausal hormone replacement therapy use in a managed care organization, 1990–95. J Gen Intern Med 2000; 15: 542–50.
   Google Scholar
• Stadberg E, Mattsson LA, Milsom I. The prevalence and severity of climacteric symptoms and the use of different treatment regimens in a Swedish population. Acta Obstet Gynecol Scand 1997; 76: 442–8.
   Google Scholar
• Pedersen AT, Lidegaard O, Kreiner S, Ottesen B. Hormone replacement therapy and risk of non-fatal stroke. Lancet 1997; 350: 1277–83.
   Google Scholar
• Backe B, Hunskaar S. Increased acceptance of HRT and improved level of information: a change in Norwegian women’s opinion from 1990 to 1997. Acta Obstet Gynecol Scand 2001; 80 (7): 623–7.
   Google Scholar
• Sogaard AJ, Tollan A, Berntsen GK, Fonnebo V, Magnus JH. Hormone replacement therapy: knowledge, attitudes, self-reported. Maturitas 2000; 35: 201–14.
   Google Scholar
• Steinberg KK, Thacker SB, Smith SJ, Stroup DF, Zack MM et al. A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer. JAMA 1991; 265: 1985–90.
   Google Scholar
• Colditz GA, Egan KM, Stampfer MJ. Hormone replacement therapy and risk of breast cancer: results from epidemiologic studies. Am J Obstet Gynecol 1993; 168: 1473–80.
   Google Scholar
• Bush TL, Whiteman M, Flaws JA. Hormone replacement therapy and breast cancer: a qualitative review. Obstet Gynecol 2001; 98: 498–508.
   Google Scholar
• Moorman PG, Kuwabara H, Millikan RC, Newman B. Menopausal hormones and breast cancer in a biracial population. Am J Public Health 2000; 90: 966–71.
   Google Scholar
• Magnusson C, Persson I, Adami HO. More about: effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J Natl Cancer Inst 2000; 92: 1183–4.
   Google Scholar
• Lando JF, Heck KE, Brett KM. Hormone replacement therapy and breast cancer risk in a nationally representative cohort. Am J Prev Med 1999; 17: 176–80.
   Google Scholar
• Olsson H, Bladstrom A, Ingvar C, Moller TR. A population-based cohort study of HRT use and breast cancer in southern Sweden. Br J Cancer 2001; 85: 674–7.
   Google Scholar
• Kuller LH. Re: Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J Natl Cancer Inst 2000; 92: 1100–1.
   Google Scholar
• Greendale GA, Reboussin BA, Sie A, Singh HR, Olson LK et al. Effects of estrogen and estrogen-progestin on mammographic parenchymal density. Postmenopausal Estrogen/Progestin Interventions (PEPI). Invest Ann Intern Med 1999; 130: 262–9.
   Google Scholar
• Marugg RC, van der Mooren MJ, Hendriks JH, Rolland R, Ruijs SH. Mammographic changes in postmenopausal women on hormonal replacement therapy. Eur Radiol 1997; 7: 749–55.
   Google Scholar
• Sendag F, Cosan TM, Ozsener S, Oztekin K, Bilgin O et al. Mammographic density changes during different postmenopausal hormone replacement therapies. Fertil Steril 2001; 76: 445–50.
   Google Scholar
• Lundstrom E, Wilczek B, von Palffy Z, Soderqvist G, von Schoultz B. Mammographic breast density during hormone replacement therapy: differences according to treatment. Am J Obstet Gynecol 1999; 181: 348–52.
   Google Scholar
• Boyd NF, Byng JW, Jong RA, Fishell EK, Little LE et al. Quantitative classification of mammographic densities and breast cancer risk: results from the Canadian National Breast Screening Study. J Natl Cancer Inst 1995; 87: 670–5.
   Google Scholar
• Persson I, Thurfjell E, Holmberg L. Effect of estrogen and estrogen-progestin replacement regimens on mammographic breast parenchymal density. J Clin Oncol 1997; 15: 3201–7.
   Google Scholar
• Hesch RD, Kenemans P. Hormonal prevention of breast cancer: proposal for a change in paradigm. Br J Obstet Gynaecol 1999; 106: 1006–18.
   Google Scholar
• Longacre TA, Bartow SA. A correlative morphologic study of human breast and endometrium in the menstrual cycle. Am J Surg Pathol 1986; 10: 382–93.
   Google Scholar
• Russo J, Russo IH. The etiopathogenesis of breast cancer prevention. Cancer Lett 1995; 90: 81–9.
   Google Scholar
• Kroman N, Wohlfahrt J, Andersen KW, Mouridsen HT, Westergaard T, Melbye M. Time since childbirth and prognosis in primary breast cancer: population based study. BMJ 1997; 315: 851–5.
   Google Scholar
• Lambe M, Hsieh C, Trichopoulos D, Ekbom A, Pavia M, Adami HO. Transient increase in the risk of breast cancer after giving birth. N Engl J Med 1994; 331: 5–9.
   Google Scholar
• Tavani A, Gallus S, La Vecchia C, Negri E, Montella M et al. Risk factors for breast cancer in women under 40 years. Eur J Cancer 1999; 35: 1361–7.
   Google Scholar
• Raafat AM, Li S, Bennett JM, Hofseth LJ, Haslam SZ. Estrogen and estrogen plus progestin act directly on the mammary gland to increase proliferation in a postmenopausal mouse model. J Cell Physiol 2001; 187: 81–9.
   Google Scholar
• Pasqualini JR, Paris J, Sitruk-Ware R, Chetrite G, Botella J. Progestins and breast cancer. J Steroid Biochem Mol Biol 1998; 65: 225–35.
   Google Scholar
• Shi YE, Liu YE, Lippman ME, Dickson RB. Progestins and antiprogestins in mammary tumour growth and metastasis. Hum Reprod 1994; 9: 162–73.
   Google Scholar
• Clarke CL, Sutherland RL. Progestin regulation of cellular proliferation. Endocr Rev 1990; 11: 266–301.
   Google Scholar
• Groshong SD, Owen GI, Grimison B, Schauer IE, Todd MC et al. Biphasic regulation of breast cancer cell growth by progesterone: role of the cyclin-dependent kinase inhibitors, p21 and p27 (Kip1). Mol Endocrinol 1997; 11: 1593–607.
   Google Scholar
• Pike MC, Spicer DV, Dahmoush L, Press MF. Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk. Epidemiol Rev 1993; 15: 17–35.
   Google Scholar
• Campagnoli C, Biglia N, Cantamessa C, Lesca L, Sismondi P. HRT and breast cancer risk: a clue for interpreting the available data. Maturitas 1999; 33: 185–90.
   Google Scholar
• Ciocca DR, Fanelli MA. Estrogen receptors and cell proliferation in breast cancer. Trends Endocrinol Metab 1997; 8: 313–21.
   Google Scholar